Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 7 | 2023 | 371 | 0.870 |
Why?
|
| Research Personnel | 3 | 2019 | 133 | 0.700 |
Why?
|
| Internet | 2 | 2011 | 204 | 0.440 |
Why?
|
| Mentors | 5 | 2023 | 111 | 0.420 |
Why?
|
| Information Storage and Retrieval | 1 | 2011 | 30 | 0.410 |
Why?
|
| Self Care | 3 | 2019 | 150 | 0.390 |
Why?
|
| Leptin | 3 | 2017 | 115 | 0.380 |
Why?
|
| Computer Communication Networks | 2 | 2019 | 13 | 0.300 |
Why?
|
| Sarcoidosis | 1 | 2007 | 11 | 0.300 |
Why?
|
| Comorbidity | 4 | 2007 | 606 | 0.300 |
Why?
|
| Minority Groups | 4 | 2023 | 537 | 0.290 |
Why?
|
| Georgia | 7 | 2023 | 155 | 0.290 |
Why?
|
| Electronic Health Records | 2 | 2019 | 65 | 0.290 |
Why?
|
| Obesity | 4 | 2021 | 965 | 0.280 |
Why?
|
| Humans | 42 | 2023 | 34853 | 0.280 |
Why?
|
| Patient-Centered Care | 2 | 2018 | 51 | 0.270 |
Why?
|
| Receptors, Notch | 2 | 2017 | 32 | 0.260 |
Why?
|
| Lung | 1 | 2007 | 413 | 0.250 |
Why?
|
| Quality of Health Care | 3 | 2019 | 136 | 0.240 |
Why?
|
| Physicians | 2 | 2021 | 148 | 0.220 |
Why?
|
| Blood Glucose | 3 | 2019 | 333 | 0.200 |
Why?
|
| Telemedicine | 2 | 2018 | 163 | 0.200 |
Why?
|
| Cultural Diversity | 2 | 2019 | 158 | 0.200 |
Why?
|
| Health Services Accessibility | 4 | 2011 | 531 | 0.200 |
Why?
|
| Education | 2 | 2019 | 48 | 0.190 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2011 | 28 | 0.190 |
Why?
|
| Information Dissemination | 2 | 2014 | 58 | 0.190 |
Why?
|
| Primary Health Care | 5 | 2018 | 283 | 0.180 |
Why?
|
| Hypertension | 4 | 2011 | 770 | 0.180 |
Why?
|
| Middle Aged | 18 | 2019 | 9642 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 465 | 0.180 |
Why?
|
| Medical Informatics | 1 | 2019 | 19 | 0.180 |
Why?
|
| Peer Review, Research | 1 | 2018 | 10 | 0.170 |
Why?
|
| Female | 23 | 2021 | 19873 | 0.170 |
Why?
|
| Research Support as Topic | 1 | 2018 | 75 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2018 | 10 | 0.170 |
Why?
|
| Government Programs | 1 | 2018 | 28 | 0.160 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2011 | 46 | 0.160 |
Why?
|
| Medicare | 1 | 2019 | 188 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 592 | 0.160 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 132 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 16 | 0.150 |
Why?
|
| Interleukin-1 | 1 | 2017 | 33 | 0.150 |
Why?
|
| Aspirin | 1 | 2017 | 45 | 0.150 |
Why?
|
| Male | 21 | 2019 | 18870 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2008 | 147 | 0.150 |
Why?
|
| Aged | 13 | 2019 | 6448 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 64 | 0.140 |
Why?
|
| Faculty | 3 | 2023 | 82 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 74 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 2 | 2009 | 169 | 0.140 |
Why?
|
| Schools, Medical | 2 | 2011 | 192 | 0.140 |
Why?
|
| Renal Dialysis | 2 | 2008 | 119 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 106 | 0.130 |
Why?
|
| Focus Groups | 2 | 2019 | 307 | 0.130 |
Why?
|
| United States | 7 | 2023 | 3894 | 0.130 |
Why?
|
| Disease Progression | 3 | 2017 | 580 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2017 | 1802 | 0.120 |
Why?
|
| Health Behavior | 3 | 2018 | 491 | 0.110 |
Why?
|
| Health Promotion | 2 | 2010 | 588 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2007 | 1003 | 0.110 |
Why?
|
| Registries | 3 | 2019 | 330 | 0.110 |
Why?
|
| Adult | 13 | 2011 | 11034 | 0.110 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2011 | 6 | 0.110 |
Why?
|
| PubMed | 1 | 2011 | 4 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2011 | 1961 | 0.110 |
Why?
|
| Informatics | 1 | 2011 | 3 | 0.110 |
Why?
|
| Search Engine | 1 | 2011 | 6 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2011 | 16 | 0.110 |
Why?
|
| Pulmonary Artery | 1 | 2011 | 37 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 781 | 0.100 |
Why?
|
| Community Health Centers | 2 | 2009 | 45 | 0.100 |
Why?
|
| Program Evaluation | 2 | 2023 | 316 | 0.100 |
Why?
|
| Remote Consultation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Urban Population | 2 | 2010 | 318 | 0.090 |
Why?
|
| Coronary Angiography | 2 | 2011 | 92 | 0.090 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2010 | 63 | 0.090 |
Why?
|
| Disease Management | 1 | 2010 | 61 | 0.090 |
Why?
|
| Healthcare Disparities | 2 | 2011 | 446 | 0.090 |
Why?
|
| Cross-Sectional Studies | 5 | 2010 | 2561 | 0.090 |
Why?
|
| Blood Pressure | 5 | 2018 | 613 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 66 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 58 | 0.090 |
Why?
|
| Logistic Models | 5 | 2011 | 894 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2011 | 393 | 0.090 |
Why?
|
| Community Networks | 2 | 2006 | 98 | 0.080 |
Why?
|
| Medically Uninsured | 1 | 2009 | 49 | 0.080 |
Why?
|
| Rural Health Services | 1 | 2009 | 39 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 2008 | 30 | 0.080 |
Why?
|
| Treatment Refusal | 1 | 2008 | 20 | 0.080 |
Why?
|
| Sickle Cell Trait | 1 | 2008 | 18 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 221 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2008 | 19 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 790 | 0.080 |
Why?
|
| Health Literacy | 1 | 2010 | 100 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2018 | 1349 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2007 | 608 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2008 | 140 | 0.080 |
Why?
|
| Students, Medical | 1 | 2009 | 121 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 188 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2009 | 469 | 0.080 |
Why?
|
| Radiography | 1 | 2007 | 75 | 0.080 |
Why?
|
| Erythropoiesis | 1 | 2006 | 13 | 0.070 |
Why?
|
| Chemistry, Clinical | 1 | 2006 | 1 | 0.070 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2006 | 5 | 0.070 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2006 | 3 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2006 | 62 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2006 | 81 | 0.070 |
Why?
|
| Patient Education as Topic | 3 | 2018 | 207 | 0.070 |
Why?
|
| Stroke | 1 | 2009 | 274 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2007 | 177 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2005 | 34 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2006 | 160 | 0.070 |
Why?
|
| Poverty Areas | 1 | 2005 | 37 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 2128 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2005 | 110 | 0.070 |
Why?
|
| Risk Factors | 3 | 2011 | 3414 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2005 | 82 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 1353 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 445 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 490 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 103 | 0.060 |
Why?
|
| Myocardium | 1 | 2006 | 224 | 0.060 |
Why?
|
| Substance-Related Disorders | 2 | 2009 | 685 | 0.060 |
Why?
|
| Program Development | 2 | 2018 | 225 | 0.060 |
Why?
|
| Chemokine CCL5 | 1 | 2004 | 38 | 0.060 |
Why?
|
| Malaria, Cerebral | 1 | 2004 | 31 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 68 | 0.060 |
Why?
|
| Education, Medical | 1 | 2005 | 97 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 231 | 0.060 |
Why?
|
| Cooperative Behavior | 1 | 2005 | 205 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 628 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2005 | 233 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 570 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 1426 | 0.060 |
Why?
|
| Capacity Building | 1 | 2023 | 78 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 1681 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 254 | 0.050 |
Why?
|
| Heart Failure | 1 | 2005 | 230 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1149 | 0.050 |
Why?
|
| Poverty | 3 | 2010 | 316 | 0.050 |
Why?
|
| Community Health Services | 2 | 2018 | 175 | 0.050 |
Why?
|
| Asthma | 1 | 2005 | 363 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 628 | 0.040 |
Why?
|
| Writing | 1 | 2018 | 33 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 2333 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2018 | 11 | 0.040 |
Why?
|
| Benchmarking | 1 | 2018 | 27 | 0.040 |
Why?
|
| Peer Group | 1 | 2019 | 138 | 0.040 |
Why?
|
| Career Mobility | 1 | 2018 | 24 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 424 | 0.040 |
Why?
|
| Adolescent | 4 | 2010 | 5035 | 0.040 |
Why?
|
| Prevalence | 3 | 2008 | 1425 | 0.040 |
Why?
|
| Diffusion | 1 | 2017 | 49 | 0.040 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2017 | 3 | 0.040 |
Why?
|
| Diamines | 1 | 2017 | 7 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 48 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2010 | 151 | 0.040 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2017 | 17 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2017 | 33 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2017 | 10 | 0.040 |
Why?
|
| Patient Participation | 1 | 2018 | 68 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2017 | 14 | 0.040 |
Why?
|
| Counseling | 1 | 2018 | 105 | 0.040 |
Why?
|
| Thiazoles | 1 | 2017 | 71 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2017 | 121 | 0.040 |
Why?
|
| Antibodies | 1 | 2017 | 135 | 0.040 |
Why?
|
| Health Surveys | 2 | 2009 | 358 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 269 | 0.040 |
Why?
|
| Endometrium | 1 | 2017 | 57 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 1530 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2010 | 517 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 323 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 222 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 182 | 0.030 |
Why?
|
| Ligands | 1 | 2017 | 317 | 0.030 |
Why?
|
| Nanostructures | 1 | 2017 | 133 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 309 | 0.030 |
Why?
|
| Young Adult | 3 | 2010 | 4012 | 0.030 |
Why?
|
| Water | 1 | 2017 | 283 | 0.030 |
Why?
|
| Child | 3 | 2009 | 2875 | 0.030 |
Why?
|
| Organizations | 1 | 2014 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 187 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 41 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2013 | 37 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 32 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 72 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2009 | 1318 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 89 | 0.030 |
Why?
|
| Exercise | 1 | 2018 | 524 | 0.030 |
Why?
|
| Animals | 3 | 2017 | 14307 | 0.030 |
Why?
|
| Sternotomy | 1 | 2011 | 2 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2011 | 12 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2011 | 22 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 34 | 0.030 |
Why?
|
| Body Weight | 1 | 2013 | 404 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 213 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2013 | 226 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 104 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 322 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2011 | 22 | 0.020 |
Why?
|
| Chest Pain | 1 | 2011 | 36 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 183 | 0.020 |
Why?
|
| Mice | 2 | 2013 | 5668 | 0.020 |
Why?
|
| Telephone | 1 | 2010 | 32 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2011 | 93 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 154 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 144 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 545 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2009 | 12 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 47 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 486 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 63 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 228 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 292 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 237 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 71 | 0.020 |
Why?
|
| ROC Curve | 1 | 2009 | 138 | 0.020 |
Why?
|
| Domestic Violence | 1 | 2009 | 24 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 188 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 39 | 0.020 |
Why?
|
| Social Perception | 1 | 2009 | 59 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 363 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 136 | 0.020 |
Why?
|
| Arginase | 1 | 2008 | 12 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 1014 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 356 | 0.020 |
Why?
|
| C-Peptide | 1 | 2007 | 6 | 0.020 |
Why?
|
| Arginine | 1 | 2008 | 62 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 964 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 139 | 0.020 |
Why?
|
| Fasting | 1 | 2007 | 50 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 63 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 87 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 129 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 128 | 0.020 |
Why?
|
| South Carolina | 1 | 2006 | 19 | 0.020 |
Why?
|
| Reticulocyte Count | 1 | 2006 | 3 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2006 | 6 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2006 | 9 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 429 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2006 | 5 | 0.020 |
Why?
|
| North Carolina | 1 | 2006 | 103 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 48 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 98 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2006 | 101 | 0.020 |
Why?
|
| Motor Activity | 1 | 2009 | 393 | 0.020 |
Why?
|
| Homeostasis | 1 | 2007 | 172 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 608 | 0.020 |
Why?
|
| Medical Audit | 1 | 2006 | 24 | 0.020 |
Why?
|
| Nephrology | 1 | 2005 | 17 | 0.020 |
Why?
|
| Unemployment | 1 | 2005 | 23 | 0.020 |
Why?
|
| Flowmeters | 1 | 2005 | 1 | 0.020 |
Why?
|
| Metered Dose Inhalers | 1 | 2005 | 2 | 0.020 |
Why?
|
| Insulin | 1 | 2007 | 224 | 0.020 |
Why?
|
| Teaching Materials | 1 | 2005 | 7 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2007 | 177 | 0.020 |
Why?
|
| Liver | 1 | 2008 | 447 | 0.020 |
Why?
|
| Financing, Government | 1 | 2005 | 18 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2005 | 49 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2006 | 103 | 0.020 |
Why?
|
| Group Practice | 1 | 2005 | 8 | 0.020 |
Why?
|
| Heart Rate | 1 | 2006 | 248 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2005 | 137 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2005 | 27 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2005 | 98 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 63 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 223 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 212 | 0.020 |
Why?
|
| Receptors, CCR3 | 1 | 2004 | 10 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2005 | 99 | 0.020 |
Why?
|
| Educational Status | 1 | 2005 | 295 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2004 | 59 | 0.020 |
Why?
|
| Alleles | 1 | 2005 | 284 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 775 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2009 | 587 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1152 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 214 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 430 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2009 | 541 | 0.010 |
Why?
|
| Health Personnel | 1 | 2005 | 200 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 901 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 229 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 968 | 0.010 |
Why?
|
| Alcoholism | 1 | 2005 | 220 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 707 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 284 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 528 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 638 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 903 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 1268 | 0.010 |
Why?
|